Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)

R. Pettengell, M. Długosz-Danecka, D. Andorsky, D. Belada, P. Georgiev, D. Quick, JW. Singer, SB. Singh, A. Pallis, A. Egorov, G. Salles,

. 2020 ; 188 (2) : 240-248. [pub] 20191227

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025288

PIX306 was a phase 3, randomised, single-blind, multicentre trial conducted in adult patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade 3 who relapsed after ≥1 rituximab-containing regimen and were not eligible for a stem cell transplant. Patients were randomised 1:1 to pixantrone 50 mg/m2 or gemcitabine 1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle, combined with rituximab 375 mg/m2 on day 1, for up to six cycles. Patients were followed for up to 96 weeks. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), complete response (CR) rate, overall response rate (ORR) and safety. Overall, 312 patients were randomised (median age 73·0 years). The study did not meet its primary endpoint. Median PFS [95% confidence interval (CI)] was 7·3 months (5·2-8·4) with pixantrone + rituximab (PIX + R) and 6·3 months (4·4-8·1) with gemcitabine + rituximab [GEM + R; hazard ratio (HR): 0·85; 95% CI 0·64-1·14; P = 0·28]. Median OS was 13·3 (10·1-19·8) months with PIX + R and 19·6 (12·4-31·9) months with GEM + R (HR: 1·13; 95% CI 0·83-1·53). ORR was 61·9% and 43·9% respectively and CR rate 35·5% and 21·7%. The incidence of adverse events, including cardiac events, was not statistically significant different between PIX + R and GEM + R.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025288
003      
CZ-PrNML
005      
20240313100153.0
007      
ta
008      
201125s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.16255 $2 doi
035    __
$a (PubMed)31879945
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Pettengell, R. $u St. George's Hospital, London, UK. $7 xx0314847
245    10
$a Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306) / $c R. Pettengell, M. Długosz-Danecka, D. Andorsky, D. Belada, P. Georgiev, D. Quick, JW. Singer, SB. Singh, A. Pallis, A. Egorov, G. Salles,
520    9_
$a PIX306 was a phase 3, randomised, single-blind, multicentre trial conducted in adult patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade 3 who relapsed after ≥1 rituximab-containing regimen and were not eligible for a stem cell transplant. Patients were randomised 1:1 to pixantrone 50 mg/m2 or gemcitabine 1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle, combined with rituximab 375 mg/m2 on day 1, for up to six cycles. Patients were followed for up to 96 weeks. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), complete response (CR) rate, overall response rate (ORR) and safety. Overall, 312 patients were randomised (median age 73·0 years). The study did not meet its primary endpoint. Median PFS [95% confidence interval (CI)] was 7·3 months (5·2-8·4) with pixantrone + rituximab (PIX + R) and 6·3 months (4·4-8·1) with gemcitabine + rituximab [GEM + R; hazard ratio (HR): 0·85; 95% CI 0·64-1·14; P = 0·28]. Median OS was 13·3 (10·1-19·8) months with PIX + R and 19·6 (12·4-31·9) months with GEM + R (HR: 1·13; 95% CI 0·83-1·53). ORR was 61·9% and 43·9% respectively and CR rate 35·5% and 21·7%. The incidence of adverse events, including cardiac events, was not statistically significant different between PIX + R and GEM + R.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
650    _2
$a deoxycytidin $x analogy a deriváty $x farmakologie $x terapeutické užití $7 D003841
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a isochinoliny $x farmakologie $x terapeutické užití $7 D007546
650    _2
$a nehodgkinský lymfom $x farmakoterapie $x patologie $7 D008228
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a rituximab $x farmakologie $x terapeutické užití $7 D000069283
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Długosz-Danecka, Monika $u Department of Haematology, Jagiellonian University, Krakow, Poland.
700    1_
$a Andorsky, David $u Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO, USA.
700    1_
$a Belada, David $u Clinical Haematology, 4th Department of Internal Medicine, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
700    1_
$a Georgiev, Pencho $u Clinic of Oncology and Haematology, University Multiprofile Hospital for Active Treatment "Sveti Georgi" and Medical University, Plovdiv, Bulgaria.
700    1_
$a Quick, Donald $u Joe Arrington Cancer Research Treatment Center, Lubbock, TX, USA.
700    1_
$a Singer, Jack W $u CTI Biopharma, Seattle, WA, USA. Elson S. Floyd School of Medicine, Washington State University, WA, USA.
700    1_
$a Singh, Simran B $u CTI Biopharma, Seattle, WA, USA. Elson S. Floyd School of Medicine, Washington State University, WA, USA.
700    1_
$a Pallis, Athanasios $u Institut de Recherches Internationales Servier, Suresnes, France.
700    1_
$a Egorov, Anton $u Institut de Recherches Internationales Servier, Suresnes, France.
700    1_
$a Salles, Gilles $u Haematology Department, Hospices Civils de Lyon, Université Claude Bernard Lyon-1, Pierre-Bénite, France.
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 188, č. 2 (2020), s. 240-248
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31879945 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20240313100148 $b ABA008
999    __
$a ok $b bmc $g 1599433 $s 1115974
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 188 $c 2 $d 240-248 $e 20191227 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace